Dr Dixon has spent over 25 years in Big Pharma, VC funded and publicly listed biotechnology companies. He held CSO and COO roles in Onxeo, Sensorion, Addex Therapeutics, Galapagos, Entomed and F2G where he led over ten positive proof of concept programmes in humans and was part of several new drug approval programmes. He has been involved in raising substantial investment for these programmes over this period.
Dr Nichols has spent 25 years at AstraZeneca in anti-infective drug discovery and development roles. He was formerly Director of Development Microbiology for the global phase III ceftazidime-avibactam development project and previously held directorships of the Microbiology and Development Microbiology departments at AstraZeneca.
Flic Gabbay is a pharmaceutical physician who has led numerous MAAs, NDAs and translational projects for infectious disease, respiratory and autoimmune programmes, including 10 recent antibiotic registrations. She held senior clinical development and Board roles in big pharma with global remits for over 10. She is also a committed entrepreneur, having started, led and raised substantial investment for several biotechnology companies and also service companies. She was founder chair of the Royal College of Physicians (UK) working party to set up the Faculty of Pharmaceutical Medicine in 1989 and currently is its Vice President.